Company Overview
OcyonBio provides dedicated autonomous manufacturing capacity with interconnected infrastructure and systems to support phased appropriate development for early development, pre-clinical, clinical, and commercial start. We behave more like a cGMP incubator space with all regulatory, systems capabilities, and resources to enable CMC data to support regulatory applications. Manufacturing and development spaces are designed to be autonomous while being interconnected to systems required to support clinical and commercial requirements.
OcyonBio provides a company with its own space, so there is no need to build an expensive facility. Providing flexibility to protect IP, manage schedules, resources, and new product introduction reducing overall cost and risks.
Disruptive Model
Accelerate from early clinical to commercial by providing facility, people and systems.
Cell Therapies
OcyonBio is a partnership development and manufacturing organization focused on advancing gene and cell therapies.
Own your facility
Enables facility ownership which allows for greater control over the process.
Shared Infrastructure
R+D suites, cell and gene therapy suites, virus and cell processing capabilities.
Facilities
Two buildings with over 150,000 square feet of space, cell processing capabilities in Q1, 2022, viral production capability in Q2, 2022.
Experienced Scientific and Commercial Leadership
Robert Salcedo
CO-Founder & Chief Executive Officer
Daniel Chang
CO-Founder & Chief Financial Officer
Our Management Team
Marvin Mercado
Director of Technology Transfer and Process Support
William Rodríguez
Senior Project Manager
Maria Velez
VP Quality Site Head
